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Arginase-II Induces Vascular Smooth Muscle Cell Senescence and
Apoptosis Through p66Shc and p53 Independently of Its L-Arginine
Ureahydrolase Activity: Implications for Atherosclerotic Plaque
Vulnerability
Yuyan Xiong, MSc; Yi Yu, MSc; Jean-Pierre Montani, MD; Zhihong Yang, MD; Xiu-Fen Ming, MD, PhD
Background-—Vascular smooth muscle cell (VSMC) senescence and apoptosis are involved in atherosclerotic plaque vulnerability.
Arginase-II (Arg-II) has been shown to promote vascular dysfunction and plaque vulnerability phenotypes in mice through
uncoupling of endothelial nitric oxide synthase and activation of macrophage inﬂammation. The function of Arg-II in VSMCs with
respect to plaque vulnerability is unknown. This study investigated the functions of Arg-II in VSMCs linking to plaque vulnerability.
Methods and Results-—In vitro studies were performed on VSMCs isolated from human umbilical veins, whereas in vivo studies
were performed on atherosclerosis-prone apolipoprotein E-deﬁcient (ApoE/) mice. In nonsenescent VSMCs, overexpressing
wild-type Arg-II or an L-arginine ureahydrolase inactive Arg-II mutant (H160F) caused similar effects on mitochondrial dysfunction,
cell apoptosis, and senescence, which were abrogated by silencing p66Shc or p53. The activation of p66Shc but not p53 by Arg-II
was dependent on extracellular signal-regulated kinases (ERKs) and sequential activation of 40S ribosomal protein S6 kinase 1
(S6K1)—c-Jun N-terminal kinases (JNKs). In senescent VSMCs, Arg-II and S6K1, ERK-p66Shc, and p53 signaling levels were
increased. Silencing Arg-II reduced all these signalings and cell senescence/apoptosis. Conversely, silencing p66Shc reduced ERK
and S6K1 signaling and Arg-II levels and cell senescence/apoptosis. Furthermore, genetic ablation of Arg-II in ApoE/ mice
reduced the aforementioned signaling and apoptotic VSMCs in the plaque of aortic roots.
Conclusions-—Arg-II, independently of its L-arginine ureahydrolase activity, promotes mitochondrial dysfunction leading to VSMC
senescence/apoptosis through complex positive crosstalk among S6K1-JNK, ERK, p66Shc, and p53, contributing to
atherosclerotic vulnerability phenotypes in mice. ( J Am Heart Assoc. 2013;2:e000096 doi: 10.1161/JAHA.113.000096)
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T he rupture of an unstable plaque with thromboticocclusion of coronary arteries is a fatal complication of
atherosclerosis, leading to acute coronary syndromes, that is,
unstable angina, myocardial infarction, and sudden cardiac
death.1,2 Unstable plaque is characterized by a thin ﬁbrous
cap overlying a large necrotic lipid core containing inﬁltrated
inﬂammatory cells with lower vascular smooth muscle cell
(VSMC) content and extracellular matrix.1,2 Senescence and
apoptosis of VSMCs have been shown to be important
contributors to plaque vulnerability.3–5 The senescent VSMCs
reveal impaired plaque-repairing capacity, whereas cell apop-
tosis causes loss of cellularity in the plaque, conferring plaque
vulnerability. In advanced atherosclerotic lesions obtained
from patients, senescent VSMCs are found in ﬁbrous caps and
intima and exhibit increased oxidative stress.5 Senescence is
characterized by the irreversible loss of the proliferative
capability of the cells, which show typical morphological
features such as large ﬂattened shape accompanied by an
increase in several senescent markers including enhanced
senescence-associated b-galactosidase (SA-b-gal) activity,
activation of p53 and increased oxidative stress, shortened
telomeres, and elevated levels of a series of cyclin-dependent
kinase inhibitors, including p16ink4, p21cip1, or p27kip1
proteins.6 In addition to senescence, VSMC apoptosis has
also been identiﬁed in advanced atherosclerotic plaques and
is increased in unstable versus stable lesions.7 Cellular
apoptosis is the process of programmed cell death that is
characterized by distinct morphological and biochemical
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alterations, including mitochondrial dysfunction, activation of
caspase-3, DNA damage such as DNA strand breaks, which
can be detected by the terminal dUTP nick end-labeling
(TUNEL) method, and externalization of phosphatidylserine
residues on the outer plasma membrane of apoptotic cells,
which can be assayed by annexin V staining.8
Compelling evidence suggests that the overwhelming
production of reactive oxygen species (ROS) promotes both
cellular senescence and apoptosis and accelerates athero-
genesis.9–11 Studies in past years have demonstrated that
mitochondria are the important source of intracellular ROS,
including O2
•– and H2O2, which ultimately cause cell senes-
cence and apoptosis.12–14 Among the mechanisms, the
mitochondrial redox enzyme p66Shc has been shown to play
an important role in mitochondrial ROS generation. On
phosphorylation at serine 36 (p66Shc-S36), p66Shc translo-
cates into mitochondria, where it directly generates H2O2 by
transferring electron from cytochrome c to oxygen, promoting
cellular senescence and apoptosis.15,16 Phosphorylation of
p66Shc-S36 has been reported to be mediated by protein
kinases including protein kinase C-b (PKC-b), extracellular
signal-regulated kinases (ERKs), and c-Jun N-terminal kinases
(JNKs).16–18 These mechanisms are implicated in organism
aging and aging-associated pathologies, including oxidative
stress, cellular senescence and apoptosis, and vascular
disease.11,19
Interestingly, arginase-II (Arg-II), an L-arginine ureahydro-
lase metabolizing L-arginine to urea and L-ornithine, is mainly
localized in the mitochondria of cells and has been shown to
exert similar biological functions as p66Shc. Both Arg-II and
p66Shc increase mitochondrial ROS production, accelerate
endothelial senescence and dysfunction, and promote ath-
erogenesis in mouse models.11,19–21 Our recent studies
demonstrated that Arg-II promotes mitochondrial ROS gener-
ation in macrophages20 and positively regulates 40S ribo-
somal protein S6 kinase 1 (S6K1) signaling, leading to
induction of endothelial nitric oxide synthase (eNOS) uncou-
pling, that is, enhanced ROS and decreased NO production
from eNOS in endothelial cells.21 S6K1 is a serine/threonine
kinase that phosphorylates the 40S ribosomal protein S6, the
ﬁrst identiﬁed S6K1 substrate, resulting in enhanced protein
translation.22 The activation of S6K1 relies on the coordinated
phosphorylation of Thr389 and Thr229 by mammalian target
of rapamycin (mTOR) and phosphoinositide-dependent
kinase-1, respectively.23,24 It is a key mediator of mTOR
complex 1 (mTORC1), which senses and integrates a variety
of environmental cues to regulate many major cellular
functions, including cell growth, cell survival, and cell motility.25
Exaggerated persistent activation of mTORC1-S6K1 signal-
ing is implicated in many aging-associated pathological
conditions including cancer, obesity, neurodegeneration, and
cardiovascular disease.25–27
It has been reported that Arg-II is involved in hypoxia-induced
VSMC proliferation,28 which does not seem to support the
observation of a more stable plaque phenotype in atheroscle-
rosis-prone apolipoprotein E (ApoE)–deﬁcient mice with Arg-II
deﬁciency (ApoE/Arg-II/) compared with ApoE/
Arg-II+/+ control mice, that is, a decreased number of proin-
ﬂammatory macrophages in the plaque, smaller size of necrotic
core, and decreased amounts of various proinﬂammatory
cytokinesandMMPs in theplaques.20Given that Arg-II enhances
mitochondrial ROS production,20 which is an important mech-
anismof both cellular senescence and apoptosis,9 in the present
study, we investigated the functional role of Arg-II in in vitro
cultured human VSMCs and in a mouse model in the context of
atherosclerotic plaque-vulnerable phenotypes and explored a
novel function of Arg-II, that is, an L-arginine ureahydrolase
activity–independent effect on activation of p53 and various
signaling pathways that activate p66Shc in VSMCs, leading to
mitochondrial dysfunction, cell senescence, and cell apoptosis.
Methods
Materials
If not speciﬁcally indicated, all chemicals including those used
for immunoblotting, mouse anti-tubulin monoclonal antibody,
and 20,70-dichloroﬂuorescein (H2DCF, #35845) were obtained
from Sigma (Buchs, Switzerland). Nx-hydroxy-nor-L-arginine
(nor-NOHA; #399275), S-12-bromoethyl-L-cystine HCl (BEC;
#197900), G€o6976 (#365250), and PD98059 (#513000) were
from Calbiochem (VWR, Geneva, Switzerland). SP600125
(#1496) was from Tocris (Anawa, Z€urich, Switzerland). Rabbit
antibodies against phospho-S6-S235/236 (#2211s), S6
(#2217s), phospho-p53-S15 (#9284s), phospho-ERK-T202/
Y204 (#9101s), and mouse anti-p53 (#2524s) for immunoﬂu-
orescence staining were from Cell Signaling (Allschwil, Swit-
zerland); mouse anti-eNOS (#610297), mouse anti-S6K1
(#611260) for immunoblotting, and mouse anti-ERK
(#610123) were from BD Transduction Laboratories (Allschwil,
Switzerland); rabbit anti-Arg-II (sc-20151) and rabbit anti-p53
(sc-6243) for immunoblotting were from Santa-Cruz (Nunnin-
gen, Switzerland). PhosphoDetect mouse anti-p66Shc
(p66Shc-Ser36; #566807) was purchased from Millipore
(Zug, Switzerland). Rabbit anti-p66Shc (#06-203) was from
Upstate (LucernaChem, Lucerne, Switzerland). Rabbit and
mouse anti-a-smooth muscle actin (a-SMA; #ab5694 and
#ab7817, respectively), rabbit anti–proliferating cell nuclear
antigen (PCNA; #ab18197) and mouse anti-S6K1 (#ab119252)
for immunoﬂuorescence staining were from Abcam (Cambridge,
UK). Alexa Fluor 680–conjugated anti-mouse IgG (#A21057),
Alexa Fluor 488–conjugated goat anti-mouse IgG, Alexa Fluor
594–conjugated goat anti-rabbit F(ab)2, dihydroethidium
(DHE), MitoSox, and 406-diamidino-2-phenyl-indole, dihydro-
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chloride (DAPI) were from Molecular Probes/Invitrogen
(Lucerne, Switzerland); IRDye800-conjugated anti-rabbit IgG
(#926-32211) was from LI-COR Biosciences (Bad Homburg,
Germany); the membrane-permeable 4,5-diaminoﬂuoresceine
acetate (DAF-2DA) was from VWR International SA (Dietikon,
Switzerland); and X-gal was from Promega (D€ubendorf, Swit-
zerland). All cell culture media and materials were purchased
from Gibco BRL (Lucerne, Switzerland).
Cell Culture
VSMCs were isolated from human umbilical veins and
cultured in Dulbecco’s Modiﬁed Eagle Medium (DMEM)
culture medium containing 10% fetal calf serum (FCS),
5.5 mmol/L glucose, 100 U/mL penicillin, 0.17 mmol/L
streptomycin, and 2 mmol/L L-glutamine. Cells of passages
2 to 4 (P2 to P4) were used as “young” cells. Some of the cells
were further split in a ratio of 1:3 continuously over a period
of several weeks until replicative senescence was reached, as
assessed by SA-b-gal staining (P20 to P23, which were
referred to as senescent cells). VSMCs isolated from 18
individual human umbilical cords were used in this study. The
“n” for number of experiments conducted with VSMCs in the
ﬁgures represents the number of repeated sets of individual
experiments, not the number of human samples.
Animals
The ApoE/ mice were from Jackson Laboratory. The
Arg-II/ mice were kindly provided by Dr William O’Brien29
and backcrossed to C57BL/6J for more than 8 generations.
Genotyping was performed by polymerase chain reaction as
previously described.29 The ApoE/ mice and Arg-II/
mice, both on a C57BL/6J background, were interbred to
obtain ApoE/Arg-II/ mice as described previously.20 To
accelerate the atherosclerotic lesion formation, 10-week-old
male ApoE/Arg-II+/+ and ApoE/Arg-II/ mice were fed
a high-fat diet (HF; energy content: 55% fat, 21% protein, and
24% carbohydrate; Harlan Teklad TD 93075) for 10 weeks. At
20 weeks of age, animals were anesthetized with ketamine
(100 mg/kg IP) and xylazine (10 mg/kg IP), the entire aortas
from the heart to the iliac bifurcation were removed and
dissected free from fat and adhering perivascular tissue for
immunoblotting analysis. For immunostaining, the aortic roots
(ARs) were snap-frozen in optimal cutting temperature
compound. The 7-lm-thick cryosections of the ARs were
stained with an In Situ Cell Death Detection Kit, TMR red
(#12156792910; Roche Applied Science), for apoptotic cells
followed by immunostaining of VSMCs with anti-a-SMA. Four
mice of each genotype were included in experiments. Housing
and animal experimentation were approved by the Swiss
Federal Veterinary Ofﬁce.
Immunoﬂuorescence Staining of ARs and VSMCs
AR cryosections (7 lm) were ﬁxed with 4% paraformaldehyde
and blocked with 2% bovine serum albumin in phosphate-buf-
fered saline (PBS) for 30 minutes. To assess the changes in
Arg-II, p66Shc, p53, and PCNA in VSMCs in aortas, costaining of
these proteins with a-SMA was performed. Mouse anti-a-SMA
was used for costaining with rabbit antibodies against Arg-II,
p66Shc, p53-S15, and PCNA, whereas rabbit anti-a-SMA was
used for costaining with mouse anti-p53 and anti-S6K1. The
sections were ﬁrst incubated for 2 hours with both anti-a-SMA
and the corresponding primary antibody. After washing, the
sections were incubated with Alexa Fluor 488–conjugated goat
anti-mouse IgG and Alexa Fluor 594–conjugated goat anti-
rabbit F(ab)2 at room temperature for 1 hour. The sections were
ﬁnally counterstained with 300 nmol/L DAPI for 2 minutes.
The immunoﬂuorescence signals were visualized under a Leica
DIM6000 confocal microscope. The same procedure was
applied for immunoﬂuorescence staining of the VSMCs that
were cultured on a coverslip, except that the cells were stained
with a single ﬁrst antibody.
Recombinant Adenovirus
Generation of recombinant adenovirus (rAd)–expressing
shRNA targeting human p66Shc and p53 driven by the U6
promoter (rAd/U6-hp66ShcshRNA and -hp53shRNA, respec-
tively) and wild-type p66Shc and a dominant-negative mutant
of p66Shc (p66Shc-S36A)30 driven by the cytomegalovirus
(CMV) promoter (rAd/CMV-p66Shc and -p66Shc-S36A,
respectively) was carried out with Gateway Technology
(Invitrogen Life Technologies) according to the manufacturer’s
instructions.31 Expression plasmids encoding p66Shc and
p66Shc-S36A (pcDNA3.1-His-p66Shc and -p66Shc-S36A,
respectively)32 were purchased from Addgene (Cambridge,
MA). The targeting sequences for shRNA are indicated
in boldface with only the sense strand shown:
GAATGAGTCTCTGTCATCG for the human p66Shc located
within p66Shc-speciﬁc CH2 domain33; GCGCACAGAGGAA-
GAGAATCT for human p53. rAd/U6-LacZshRNA, rAd/
U6-Arg-IIshRNA, rAd/U6-S6K1shRNA, rAd/CMV empty vector,
rAd/CMV-Arg-II, rAd/CMV-Arg-II-H160F (an L-arginine ureahy-
drolase inactive mutant of Arg-II), and rAd/CMV-HA-S6K1ca
(an active S6K1 mutant), generated as previously described.21
Adenoviral Transduction of VSMC
Transduction of VSMCs by rAd was performed as previously
described.34 Cells were transduced with the rAd at titers of 50
to 100 multiplicities of infection and cultured in complete
medium for 2 to 4 days before experiments as indicated in the
ﬁgures.
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Immunoblotting
Cell or tissue lysate preparation, SDS-PAGE, and transfer of
SDS gels to Immobilon-P membranes (Millipore) were per-
formed as previously described.35 The resultant membrane
was ﬁrst incubated with the corresponding primary antibody
at room temperature for 2 hours with gentle agitation after
blocking with 5% skim milk. The blot was then further
incubated with a corresponding anti-mouse (Alexa Fluor 680–
conjugated) or anti-rabbit (IRDye 800-conjugated) secondary
antibodies. Signals were visualized using an Odyssey Infrared
Imaging System (LI-COR Biosciences). Quantiﬁcation of the
signals was performed using NIH Image 1.47 software (US
National Institutes of Health).
Arginase Activity Assay
Arginase activity was measured by colorimetric determination
of urea formed from L-arginine as previously described.36
Brieﬂy, cells were lysed in lysis buffer containing 10 mmol/L
Tris-HCl (pH 7.4), 0.4% Triton X-100, 10 lg/mL leupeptin,
and 0.1 mmol/L phenylmethylsulfonyl ﬂuoride (PMSF). Sam-
ples were centrifuged at 13 000 rpm at 4°C for 10 minutes,
and protein concentration of the supernatant was determined
by the Lowry method (Bio-Rad). For measurement of arginase
activity, equal amount of the cell lysate in 50 lL (2 lg total
protein for young cells overexpressing LacZ, Arg-II, or
Arg-II-H160F; 30 lg total protein for comparison between
young and senescent VSMCs) was added to 50 lL of Tris-HCl
(10 mmol/L [pH 7.4]) containing 5 mmol/L MnCl2. Arginase
was then activated by heating the mixture at 56°C for
10 minutes. The hydrolysis reaction of L-arginine by arginase
was conducted by incubating the mixture containing activated
arginase with 100 lL of L-arginine (100 mmol/L [pH 9.6]) at
37°C for 1 hour. For colorimetric determination of urea, 1 mL
of chromogenic reagent consisting of 1 volume of 3%
2,3-butanedione monoxine and 29 volumes of the acid
solution mixture (H2SO4:H3PO4:H2O 1:3:7) was added, and
the mixture was then heated at 100°C for 30 minutes. After
placing the samples in the dark for 10 minutes at room
temperature, the urea concentration was determined spec-
trophotometrically by the absorbance at 492 nm. The amount
of the urea produced was used as an index for arginase
activity.
Detection of Nitric Oxide (NO), Cytoplasmic O2
•,
Mitochondrial O2
•, and H2O2
NO, cytoplasmic O2
•, mitochondrial O2
•, and H2O2 detec-
tion was performed by using DAF-2DA, DHE, MitoSox, and
H2DCF, respectively, as previously described.
20,35 For detec-
tion of NO, cells were gently washed twice with Ca2+-free PBS
and incubated in a modiﬁed Krebs–Ringer bicarbonate solution
(NaCl, 118 mmol/L; KCl, 4.7 mmol/L; CaCl2, 2.5 mmol/L;
MgSO4, 1.2 mmol/L; KH2PO4, 1.2 mmol/L; NaHCO3,
25 mmol/L; EDTA, 0.026 mmol/L; and glucose, 5.5 mmol/L)
containing 5 lmol/L of DAF-2DA for 30 minutes. For detec-
tion of cytoplasmic or mitochondrial superoxide, cells were
incubated with 5 lmol/L DHE for 20 minutes or 5 lmol/L
MitoSox for 10 minutes, respectively. For detection of H2O2,
cells were washed with PBS and incubated with 10 lmol/L
H2DCF in PBS for 25 minutes. The cells were then washed 3
times and ﬁxed with 3.7% of paraformaldehyde, and images
were obtained with Zeiss ﬂuorescence microscopy. The inten-
sity of the ﬂuorescence was quantiﬁed by NIH Image J 1.47
software and normalized by cell number.
Mitochondrial Membrane Potential
Mitochrondrial membrane (Dwm) was assessed using a JC-1
Mitochondrial Membrane Potential Detection Kit
(#10009172; Cayman) according to the manufacturer’s
instructions. In healthy cells with high mitochondrial Dwm,
JC-1 spontaneously forms complexes known as J-aggregates
with intense red ﬂuorescence that was detected at 600-nm
emission after excitation at 550 nm. On the other hand, in
apoptotic or unhealthy cells with low Dwm, JC-1 remains in
the monomeric form, which shows only green ﬂuorescence
that was detected at 535-nm emission after excitation at
485 nm. Quantiﬁcation of the signals was performed using
NIH Image 1.47 software.
SA-b-gal staining
SA-b-gal staining was performed as previously described.35
Brieﬂy, cells were washed twice with PBS followed by ﬁxation
with a 3.7% formaldehyde solution for 10 minutes. After
washing, cells were then incubated with the SA-b-gal staining
solution (1 mg/mL X-gal, 40 mmol/L citric acid, 5 mmol/L
potassium ferrocyanide, 5 mmol/L potassium ferricyanide,
150 mmol/L sodium chloride, 2 mmol/L magnesium chloride
dissolved in phosphate buffer) at pH 6.0 overnight at 37°C in
a CO2-free atmosphere. The stained senescent cells were
detected by conventional microscopy. Senescent cells were
determined by the ratio of SA-b-gal-positive cells to the total
cell count.
Detection of Apoptotic Cells
Apoptosis of cultured VSMCs was detected with an Annex-
in-V-FLUOS Staining Kit (#1988549; Roche Applied Science),
whereas detection of apoptotic cells in atherosclerotic plaque
was carried out by staining of the 7-lm-thick cryosections of
the aortic roots with the In Situ Cell Death Detection Kit, TMR
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red (TUNEL; #12156792910; Roche Applied Science) accord-
ing to the manufacturer’s instructions. Quantiﬁcation of the
signals was performed using NIH Image 1.47 software.
Assessment of Cell Proliferation
Proliferation of cultured VSMCs was assessed by monitoring
the proliferation marker PCNA37 by immunoblotting and/or
immunostaining.
Statistical Analysis
Statistical analysis was performed as described previously.20
In brief, the Kolmogorov–Smirnov test was used to ﬁrst
determine whether the data deviated from Gaussian distribu-
tions. For normally distributed values, statistical analysis was
performed with the Student t test for unpaired observations or
analysis of variance (ANOVA) with Bonferroni’s posttest, and
data are given as meansSEMs. For nonnormally distributed
values, nonparametric statistical analysis was performed with
the Mann–Whitney test or the Kruskal–Wallis test with a
Dunn’s multiple comparison posttest, and data are expressed
as medians with 25th and 75th percentiles. P≤0.05 was
considered a statistically signiﬁcant difference. The number of
treatment groups in each set of experiment and the “n”
(number of repeated sets of in vitro experiments conducted
with human VSMCs or the number of animals of each
genotype used) is indicated in each ﬁgure.
Results
Effects of Overexpression of Arg-II in Young
VSMCs
Arg-II overexpression induces oxidative stress and
mitochondrial dysfunction in VSMCs
In the young VSMCs, overexpression of wild-type Arg-II and of
the L-arginine ureahydrolase inactive mutant H160F21 was
conﬁrmed by immunoblotting with the antibody that reacts
with both wild-type and mutant Arg-II, and the activity of the
wild-type and mutant enzymes was conﬁrmed by the arginase
activity assay (Figure 1A). Overexpression of Arg-II in the cells
enhances cytosolic O2
• (assessed by DHE staining), mito-
chondrial O2
• production (assessed by MitoSox staining),
and H2O2 generation (assessed by H2DCF staining) (Fig-
ure 1B). Interestingly, the inactive Arg-II mutant (H160F) with
abolished L-arginine ureahydrolase activity, as shown in
Figure 1A, was unable to stimulate O2
• production but was
still able to induce H2O2 (Figure 1B). The results demonstrate
that Arg-II exerts both an L-arginine ureahydrolase activity–
dependent effect (generation of O2
•) and an enzymatic
activity–independent effect, that is, generation of H2O2 in
VSMCs. In addition, mitochondrial membrane potential (Dwm)
as assessed by JC-1 staining (red ﬂuorescent JC-1 signal is
indicative of healthy cells with high Dwm, whereas green
ﬂuorescent JC-1 signal is indicative of unhealthy cells with low
Dwm) was signiﬁcantly attenuated in the VSMCs overex-
pressing Arg-II or the inactive H160F mutant (Figure 1C).
These results demonstrate that Arg-II decreases mitochon-
drial Dwm and induces H2O2 production in VSMCs indepen-
dently of its L-arginine ureahydrolase activity. For the following
study, we mainly focused on the novel enzymatic activity–
independent effects of Arg-II. Moreover, there was no NO
production as assessed by DAF-2DA (Figure 2A) and no
detectable expression of eNOS or inducible nitric oxide
synthase (iNOS) (Figure 2B), demonstrating that Arg-II’s
effects in VSMCs are independent of NOS/NO.
Arg-II overexpression promotes VSMC senescence and
apoptosis independently of its L-arginine ureahydrolase
activity but enhances VSMC proliferation in an
enzymatic activity–dependent manner
Overexpression of Arg-II in the young VSMCs promoted cell
senescence as demonstrated by the increase in the percent-
age of the cells positive for SA-b-gal staining (Figure 3A).
Moreover, more apoptotic cells as demonstrated by positive
Annexin-V-FLUOS staining were observed in cells overex-
pressing Arg-II (Figure 3B). In addition, p53-S15 levels were
increased by overexpressing Arg-II, although total p53 levels
were not altered (Figure 3C). In line with its effects in
promoting H2O2 production and mitochondrial dysfunction,
the inactive Arg-II mutant H160F exerted similar effects in
inducing cellular senescence, apoptosis, and p53-S15 similar
to those in wild-type Arg-II (Figure 3A through 3C). In
contrast, only the wild type, not the inactive mutant H160F,
showed a stimulatory effect on cell proliferation as monitored
by the proliferation marker PCNA with immunoblotting
(Figure 3C) or by immunostaining (Figure 3D). These data
demonstrate that Arg-II promotes VSMC senescence and
apoptosis through an L-arginine ureahydrolase activity–inde-
pendent mechanism, whereas it stimulates VSMC prolifera-
tion in an enzymatic activity–dependent manner (please also
refer to the scheme in Figure 17A).
Arg-II overexpression activates p66Shc through S6K1
in VSMC independently of its enzymatic activity
To elucidate the mechanisms of Arg-II in inducing VSMC
mitochondrial dysfunction, cell senescence, and apoptosis,
the effects of Arg-II on the mTORC1-S6K1 signaling pathway
and the mitochondrial redox protein p66Shc were investi-
gated. The cells overexpressing Arg-II reveal enhanced levels
of S6K1-T389, S6-S235/236, and p66Shc-S36, as well as of
total p66Shc (Figure 4A). Similar effects were obtained with
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the inactive Arg-II mutant H160F (Figure 4A), demonstrating
an Arg-II enzymatic activity–independent effect on activation
of S6K1 and p66Shc. Furthermore, treatment of the young
VSMCs with the arginase inhibitors BEC (200 lmol/L) or
nor-NOHA (50 lmol/L) overnight did not affect the stimulat-
ing effect of Arg-II overexpression on S6K1 and p66Shc
activation (Figure 4B). These results further support our
conclusion on the enzymatic activity–independent effect of
Arg-II on S6K1 and p66Shc. Moreover, silencing S6K1
abrogated the Arg-II-induced increase in p66Shc-S36 and
total p66Shc levels, whereas elevated p53-S15 on Arg-II
overexpression was not affected by silencing S6K1 (Figure 5).
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Figure 1. Arginase-II (Arg-II) overexpression enhances cytoplasmic and mitochondrial O2• generation in an L-arginine ureahydrolase
activity-dependent manner, promotes production of H2O2, and decreases mitochondrial membrane potential (Dwm) independently of its enzymatic
activity in young VSMCs. Young VSMCs were transduced with empty vector rAd/CMV as control (con), rAd/CMV-Arg-II (Arg-II), or rAd/
CMV-Arg-II-H160F (H160F, an inactive Arg-II mutant). Seventy-two hours posttransduction, the cells were subjected to (A) immunoblotting analysis
for detection of overexpressed Arg-II taking tubulin as a loading control (left) and arginase activity assay (right). B, DHE and MitoSox staining for
detection of cytoplasmic and mitochondrial O2
•, respectively, and H2DCF staining for detection of H2O2 production. C, Dwm assessment using a
JC-1 Mitochondrial Membrane Potential Detection Kit. Red ﬂuorescence JC-1 signal is indicative of healthy cells with high Dwm, whereas green
ﬂuorescence JC-1 signal is indicative of unhealthy cells with low Dwm. Quantiﬁcation of the signals is shown in the corresponding right-sided panels
(n=6 or 8 as indicated in the graphs). **P<0.01, ***P<0.001 vs control group, ###P<0.001 vs Arg-II. Scale bar=0.2 mm. VSMC indicates vascular
smooth muscle cell; rAd, recombinant adenovirus; DHE, dihydroethidium; H2DCF, 20,70-dichloroﬂuorescein; CMV, cytomegalovirus.
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These results demonstrate that Arg-II activates p66Shc
through S6K1 signaling, whereas activation of p53 by Arg-II
is independent of S6K1 in the VSMCs (please also refer to the
scheme in Figure 17A).
Silencing p66Shc prevents the effects of Arg-II
overexpression in VSMCs
We further investigated whether p66Shc mediates Arg-II-
induced mitochondrial dysfunction, cell senescence, and cell
apoptosis. For this purpose, p66Shc was knocked down in the
VSMCs overexpressing Arg-II. The expression of Arg-II and the
silencing effect of p66Shc were validated by immunoblotting
(Figure 6). The results showed that silencing p66Shc does not
affect the effect of Arg-II overexpression-mediated activation of
S6K1 or p53-S15 (Figure 6), demonstrating that p66Shc
functions downstream of S6K1 and that p53 activation by
Arg-II is independent of the S6K1-p66Shc pathway (please also
refer to the scheme in Figure 17A). Moreover, silencing p66Shc
abolished mitochondrial H2O2 production (Figure 7A) and
prevented the decrease in Dwm (Figure 7B) as well as the cell
senescence (Figure 7C) and apoptosis (Figure 7D) induced by
Arg-II overexpression in the young VSMCs, demonstrating that
p66Shc indeed mediates the effects of Arg-II in VSMC.
Mechanisms of S6K1-induced p66Shc activation
in VSMCs
Because PKC-b, ERK, and JNK have been reported to be
involved in phosphorylation of p66Shc-S36,16–18 we further
investigated whether these signaling molecules are involved in
S6K1-mediated phosphorylation/activation of p66Shc in the
young cells overexpressing Arg-II. Treatment of the cells with
the speciﬁc inhibitors of these signaling pathways overnight
showed that the Arg-II overexpression–induced activation of
S6K1 (monitored by increased S6-S235/236) was not
affected by the inhibitors of these signaling pathways
including the PKC-a/b1 inhibitor G€o6976 (1 lmol/L;
Figure 8A), PKC-b2 inhibitor CGP53353 (1 lmol/L; Figure 8B),
ERK inhibitor PD98059 (50 lmol/L; Figure 8A), and JNK
inhibitor SP600125 (20 lmol/L; Figure 8A). However, acti-
vation of p66Shc (p66Shc-S36) by Arg-II overexpression was
inhibited by PD98059 or SP600125, but not by G€o6976
(Figure 8A) or by CGP53353 (Figure 8B). These results
demonstrate that ERK and JNK (not PKC-a/b), in addition to
S6K1 (see Figure 5), are required for Arg-II-induced activation
of p66Shc.
The relationship between S6K1, ERKs, and JNK in activa-
tion of p66Shc was further investigated in the young cells
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Figure 2. NOS/NO is not involved in the actions of Arg-II in VSMCs. VSMCs were transduced with empty vector rAd/CMV as control or rAd/
CMV-Arg-II. Seventy-two hours posttransduction, cells were treated with 5 mmol/L L-NG-Nitroarginine methyl ester (L-NAME) for 1.5 hours and
then subjected to (A) DAF-2DA staining for nitric oxide (NO) production. Human umbilical veins endothelial cells (HUVECs) were used as a positive
control for NO staining. B, Immunoblotting analysis of iNOS and eNOS (P, positive control). Macrophage (Pm) was used as a positive control for
iNOS (left), whereas HUVECs (Pe) was used as a positive control for eNOS (right). Scale bar=0.2 mm. These experiments were repeated 3 times.
NOS indicates nitric oxide synthase; VSMC, vascular smooth muscle cell; con, control; rAd, recombinant adenovirus; DAF-2DA, 4,5-diamino-
ﬂuoresceine acetate; iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase; Arg-II, arginase-II.
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Figure 3. Overexpression of Arg-II in young VSMCs causes cell senescence and apoptosis independently of its enzymatic activity, whereas it
enhances cell proliferation in an enzymatic activity–dependent manner. The young VSMCs were as described in Figure 1. A, SA-b-gal staining for
senescent cells. B, Annexin-V-FLUOS staining for detection of apoptotic cells. C, Immunoblotting analysis of p53-S15, p53, PCNA, and Arg-II
levels. Tubulin served as a loading control. D, Representative images showing immunoﬂuorescence staining of PCNA level (red) in VSMCs followed
by counterstaining with DAPI (blue). The merged images are also shown. Bar graphs show quantiﬁcations of the corresponding signals (n=6 or 3).
*P<0.05, **P<0.01, ***P<0.001 vs control. Scale bar=0.2 mm. Arg-II indicates arginase-II; VSMC, vascular smooth muscle cell; con, control;
SA-b-gal, senescence-associated b-galactosidase; PCNA, proliferating cell nuclear antigen; DAPI, 406-diamidino-2-phenyl-indole, dihydrochloride.
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overexpressing an active S6K1 mutant (S6K1ca). As shown in
Figure 8C, the increase in p66Shc-S36 level on overexpres-
sion of S6K1ca was not affected by the ERK inhibitor
PD98059, but was abolished by the JNK inhibitor SP600125.
These results together with those presented in Figure 5
demonstrate that Arg-II overexpression in young cells acti-
vates p66Shc, requiring 2 independent pathways, the S6K1-JNK
and ERK pathways (please refer to the scheme presented in
Figure 17A).
Effects of Arg-II on VSMCs are dependent on
p66Shc-S36 phosphorylation and p53
Next, we investigated whether the effects of p66Shc are
dependent on its phosphorylation at S36. For this purpose, the
dominant-negative p66Shc mutant in which serine-36 was
mutated to alanine (S36A)30 was expressed together with Arg-II
in the young VSMCs (Figure 9A, left). The results showed that
the stimulating effects of Arg-II on H2O2 generation (Figure 9B),
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Figure 4. Overexpression of Arg-II in young VSMCs activates S6K1 and p66Shc independently of its enzymatic activity. A, Young VSMCs were
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mitochondrial dysfunction (Figure 9C), cell senescence (Fig-
ure 9D), and cell apoptosis (Figure 9E) are further enhanced by
coexpression of wild-type p66Shc but are signiﬁcantly inhibited
by coexpression of the S36A mutant, demonstrating the
functional importance of the phosphorylation of p66Shc at
S36 in the cellular effects mediated by Arg-II.
Furthermore, we examinedwhether p53,which is activated by
Arg-II independently from the S6K1-JNK-p66Shc pathway, is also
involved in the actions of Arg-II in VSMCs. Silencing p53 also
inhibited Arg-II-mediated cellular effects including H2O2 produc-
tion, mitochondrial dysfunction, senescence, and apoptosis
(Figure 9A through 9E, the last lane or bar). These data
demonstrate that both the S6K1-JNK-p66Shc and p53 pathways,
which are independently activated by Arg-II as shown by above
experiments, are required for the actions of Arg-II in VSMCs.
Effects of Silencing Arg-II in Senescent VSMCs
Enhanced activation of Arg-II-S6K1-p66Shc and p53
and decreased cell proliferation in senescent VSMCs
Next, we examined the effects of Arg-II in senescent VSMCs.
Compared with the young VSMCs, the senescent cells
exhibited elevated arginase activity, which is associated with
predominantly increased expression of Arg-II (Arg-I expression
was very low, although it was also increased in senescent
cells; Figure 10), suggesting that Arg-II plays a dominant role,
which is similar to that in human endothelial cells.36 Enhanced
levels of S6K1-T389, total S6K1, p66Shc-S36, total p66Shc,
p53-S15, and total p53 were also observed, whereas the
PCNA level was decreased in the senescent VSMCs
(Figure 10), which is in line with the irreversible growth
arrest characteristic of cell senescence.
Effects of silencing Arg-II or p53 and the importance of
p66Shc-S36 in senescent cell dysfunctions
Silencing Arg-II in the senescent VSMCs suppressed almost all
the senescence-associated signaling, including S6K1-T389 and
total S6K1, S6-S235/236 and total S6, p66Shc-S36, and total
p66Shc, as well as p53-S15, but not total p53 (Figure 11A). The
cell proliferation, as assessed by PCNA level with immunoblot-
ting and immunostaining, which was decreased in the senes-
cent VSMCs as shown in Figure 10, was further signiﬁcantly
reduced by Arg-II silencing (Figure 11B), demonstrating that
Arg-II supports VSMC proliferation, which is in accordance with
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previously published studies28 and also in linewith the ﬁnding in
young cells (Figure 3C and 3D). Moreover, silencing Arg-II in the
senescent VSMCs reduced H2O2 generation, restored mito-
chondrial Dwm, and decreased SA-b-gal-positive cell number
and apoptosis (Figure 12).
In agreement with the ﬁnding in young VSMCs that p53 is
required for Arg-II-induced cellular senescence and apoptosis
(Figure 9), silencing p53 in the senescent cells exerted effects
similar to silencing Arg-II (Figure 12, the last lane). Further-
more, over expression of wild-type p66Shc in the senescent
VSMCs, which showed high Arg-II level and activity (Figure 10),
further enhanced H2O2 generation, mitochondrial dysfunction,
cell senescence, and cell apoptosis (Figure 13), whereas
over expression of the p66Shc-S36A in the cells signiﬁ-
cantly reduced these parameters (Figure 13A through 13D,
last lane), further conﬁrming the importance of S36 phos-
phorylation of p66Shc in the regulation of cellular functions.
These results together with those shown in Figure 11
demonstrate that enhanced Arg-II in senescent VSMCs
accounts for deregulation of S6K1-p66Shc and p53, leading
to mitochondrial dysfunction, cell senescence, and cell
apoptosis.
Role of JNK and ERK in S6K1 and p66Shc activation in
senescent cells
The interaction between S6K1, JNK, and ERKs in the activation
of p66Shc was also analyzed in the senescent VSMCs, which
exhibited enhanced Arg-II-S6K1-p66Shc signaling (Figure 10).
In comparison with the young cells, in the senescent cells, the
ERK inhibitor PD98059 or the JNK inhibitor SP600125 not
only inhibited p66Shc-S36, but also reduced S6K1 activity
(Figure 14A), suggesting that ERK and JNK also act upstream
of S6K1 in the senescent cells (please refer to Figure 17B).
Moreover, silencing p66Shc in senescent VSMCs reduced
activation of S6K1 and ERK and also reduced Arg-II expression
(Figure 14B). These results demonstrate that in senescent
VSMCs, p66Shc also activates ERK, JNK, and S6K1, which
upregulate expression of Arg-II. These results suggest com-
plex positive crosstalk among all the signaling components in
senescent VSMCs (see Figure 17B).
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Genetic ablation of Arg-II inhibits activation of
S6K1-p66Shc as well as p53 and protects against cell
apoptosis in atherosclerotic plaque
To further conﬁrm the role of Arg-II-S6K1-p66Shc in inducing
VSMC apoptosis linked to cardiovascular diseases such as
atherosclerosis and plaque vulnerability in vivo, we interbred
Arg-II/ mice with atherosclerosis-prone ApoE/ mice
and obtained ApoE/Arg-II/ double-knockout mice.20 To
accelerate the atherosclerotic lesion formation, ApoE/
Arg-II/ mice (at age 10 weeks) were fed a HF diet for
10 weeks. Immunoblotting analysis with the aortas revealed
reduced levels of S6K1, p66Shc-S36, p66Shc, p53-S15, p53,
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Figure 8. Effects of signaling inhibitors on Arg-II- or S6K1-induced phosphorylation of p66Shc-S36. Immunoblotting analysis of the signaling and
protein levels as indicated. A and B, Young VSMCs were transduced with empty-vector rAd/CMV as control (Arg-II:) or rAd/CMV-Arg-II (Arg-II: +).
Cells were treated with or without the signaling inhibitor overnight during serum starvation before cell lysate preparation 72 hours
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S6-S235/236, and S6 in ApoE/Arg-II/ mice compared
with the ApoE/Arg-II+/+ control animals (Figure 15).
Costaining of these proteins with a-SMA revealed that these
proteins are present in the VSMCs of aortic roots with
atherosclerotic plaques, which was more pronounced in the
ApoE/Arg-II+/+ controls than in the ApoE/Arg-II/
mice (Figure 16A). A reduced number of apoptotic VSMCs
was observed in the plaques of ApoE/Arg-II/ mice
(Figure 16B), which is in agreement with the previous report
of more stable plaque phenotypes in ApoE/Arg-II/
A.
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Figure 9. Phosphorylation of p66Shc at S36 as well as p53 signaling is required for the actions of Arg-II in young VSMCs. The young VSMCs
were ﬁrst transduced with either rAd/CMV empty vector as control (con) or rAd/CMV-p66Shc, -p66Shc-S36A; rAd/U6-LacZshRNA, or rAd/
U6-p53shRNA. Twenty-four hours after the ﬁrst transduction, the cells were then transduced with either rAd/CMV as control (con) or rAd/
CMV-Arg-II to overexpress Arg-II as indicated. Experiments were performed 72 hours after the second transduction. A, Immunoblotting analysis
showing the overexpression of p66Shc and p66Shc-S36A (left) and the efﬁcient silencing of p53 (right). B, H2DCF staining for detection of H2O2.
C, Dwm assessment by JC-1 staining. D, SA-b-gal staining for senescent cells. E, Annexin-V-FLUOS staining for apoptotic cells. Quantiﬁcation of
the signals is shown in the corresponding bar graphs (n=6). **P<0.01 vs control; †P<0.05, ††P<0.01 vs Arg II. Scale bar=0.2 mm. Of note, in B
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mice, that is, less macrophage accumulation, less production
of proinﬂammatory cytokines, and smaller necrotic cores in
ApoE/Arg-II/ mice compared with ApoE/Arg-II+/+
mice.20 These data provide in vivo evidence of an important
role for Arg-II in inducing VSMC apoptosis through activation
of S6K1-p66Shc and p53, contributing to plaque vulnerability
(Figure 17).
Discussion
Previous studies including our own demonstrated that vascu-
lar endothelial arginase is increased in numerous physiopath-
ological conditions and plays an important role in endothelial
dysfunction in aging, diabetes, and atherosclerosis.21,36,38,39
In endothelial cells, Arg-II induces an increase in ROS and a
decrease in NO production resulting from eNOS uncoupling,
which promotes endothelial senescence and inﬂammation.21
Moreover, our recent study demonstrated that Arg-II also
promotes macrophage proinﬂammatory responses through
inducing mitochondrial ROS and that genetic deﬁciency in
Arg-II in ApoE/ mice reduces atherosclerotic lesion forma-
tion and confers features of stable plaques such as reduction
in inﬂammatory macrophage accumulation, cytokine produc-
tion, and necrotic cores.20 In the present study, we uncovered
a novel mechanism by which Arg-II, independently of its
L-arginine ureahydrolase activity, promotes mitochondrial
dysfunction leading to VSMC senescence/apoptosis through
complex positive crosstalk among S6K1-JNK, ERK, p66Shc,
and p53, contributing to atherosclerotic vulnerability pheno-
types in mice.
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Figure 10. Enhanced expression and activity of arginases, S6K1, p66Shc, and p53 and decreased PCNA level in senescent VSMCs.
Immunoblotting analysis of Arg-I, Arg-II, S6K1-T389 and total S6K1, p66Shc-S36 and total p66Shc, p53-S15 and total p53, and PCNA expression,
as well as arginase activity in the senescent VSMCs (S) compared with the young cells (Y). Quantiﬁcation of the signals is shown in the
corresponding bar graphs (n=6). *P<0.05, **P<0.01, ***P<0.001 vs young cells (Y). Arg-II indicates arginase-II; VSMC, vascular smooth muscle
cell; PCNA, proliferating cell nuclear antigen; S6K1, ribosomal protein S6 kinase 1.
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Arginase Activity–Independent and –Dependent
Effects in VSMCs
One of the major ﬁndings of the study is the L-arginine
ureahydrolase activity–independent functions of Arg-II. In
agreement with the role of Arg-II in promoting cell proliferation
through its enzymatic activity,28 we found that overexpression
of wild-type Arg-II, but not of inactive Arg-II, in young VSMCs
enhances cell proliferation. In contrast to its effect on cell
proliferation, Arg-II activates S6K1-p66Shc and p53 and
promotes H2O2 production and mitochondrial dysfunction,
leading to senescence and apoptosis independently of its
enzymatic activity, as all these changes occur not only in VSMCs
overexpressing wild-type Arg-II, but also in VSMCs over-
expressing the inactive Arg-II mutant. Moreover, the enzymatic
activity–independent effects on S6K1-p66Shc were also
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Figure 11. Effects of silencing Arg-II in senescent VSMCs on activation of S6K1-p66Shc and p53 and on PCNA level. Senescent VSMCs were
transduced with either rAd/U6-LacZshRNA or rAd/U6-Arg-IIshRNA. Seventy-two hours after transduction cell lysates were prepared and subjected to
(A) immunoblotting analysis of Arg-II, tubulin, S6K1-T389 and total S6K1, S6-S235/236 and total S6, p66Shc-S36 and total p66Shc, p53-S15,
and total p53. Quantiﬁcation of the signals is shown in the right bar graphs (n=6). *P<0.05, **P<0.01 vs young cell (Y). B, Immunoblotting
analysis and immunoﬂuorescence staining of PCNA. Quantiﬁcation of the immunoblotting signals of PCNA is shown in the bar graphs underneath
the immunoblotting. *P<0.05 vs LacZ-shRNA. Arg-II indicates arginase-II; VSMC, vascular smooth muscle cell; PCNA, proliferating cell nuclear
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Figure 12. Silencing Arg-II or p53 in senescent VSMCs prevents H2O2 production and decreased Dwm as well as senescence and apoptosis.
Young (Y) and senescent (S) VSMCs were transduced with either rAd/U6-LacZshRNA or rAd/U6-Arg-IIshRNA as indicated. Seventy-two hours
posttransduction, the cells were subjected to (A) H2DCF staining for detection of H2O2. B, JC-1 staining for analysis of Dwm. C, SA-b-gal staining
for senescent cells. D, Annexin-V-FLUOS staining for apoptotic cells. Quantiﬁcation of the signals is shown in the corresponding bar graphs (n=6).
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Figure 13. Enhanced phosphorylation of p66Shc-S36 accounts for the phenotypic changes of senescent VSMCs. Senescent VSMCs were
transduced with either rAd/CMV empty vector as control (con), rAd/CMV-p66Shc or -p66Shc-S36A (S36A) as indicated. Seventy-two hours
posttransduction, the cells were subjected to (A) H2DCF staining for detection of H2O2. B, JC-1 staining for analysis of Dwm. C, SA-b-gal staining
for senescent cells. D, Annexin-V-FLUOS staining for apoptotic cells. Quantiﬁcation of the signals is shown in the corresponding bar graphs (n=6).
*P<0.05, **P<0.01 vs con. Scale bar=0.2 mm. Arg-II indicates arginase-II; VSMC, vascular smooth muscle cell; H2DCF, 20,70-dichloroﬂuorescein;
SA-b-gal, senescence-associated b-galactosidase; rAd, recombinant adenovirus.
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conﬁrmed by the lack of the effects of arginase inhibitors. Thus,
for the ﬁrst time, we provide ﬁrm evidence that Arg-II has dual
opposing functions in promoting VSMC proliferation and
senescence/apoptosis through different mechanisms. While
it promotes VSMC proliferation and cytoplasmic and mitochon-
drial O2
• in an enzymatic activity–dependent manner, it
induces H2O2 generation, mitochondrial dysfunction, and
senescence/apoptosis through parallel activation of p66Shc
and p53 independently of its enzymatic activity. Overall, the
induction of senescence/apoptosis seems to be predominant
over the induction of proliferation by Arg-II, especially in
senescent VSMCs, in which elevated Arg-II results in a cellular
outcome of senescence/apoptosis rather than proliferation,
although Arg-II is still involved in VSMC proliferation under this
condition because silencing Arg-II in senescent cells not only
reduces senescence/apoptosis but also further decreases
PCNA. Of note, enzymatic activity–independent effects have
also been reported for another urea cycle enzyme, argininosuc-
cinate lyase,40 which acts as a scaffold protein. Whether this is
also true for Arg-II requires further extensive investigation. We
wish to point out that Arg-I is expressed at a much lower level
than Arg-II and that the expression of Arg-I is also increased
in senescent VSMCs. However, silencing Arg-II in senescent
VSMCs or genetic ablation of Arg-II in mice greatly inhibited the
aging-associated signaling pathways and senescence/apopto-
sis, demonstrating the predominant role of Arg-II in VSMCs.
In contrast to endothelial cells, in which Arg-II affects cell
function mainly through interfering with eNOS function, in
VSMCs the functional role of Arg-II is independent of NOS
because neither eNOS nor iNOS nor NO production is
detectable in VSMCs under our experimental conditions. This
is in agreement with our recent study showing that Arg-II
promotes proinﬂammatory responses in macrophages through
enhancing mitochondrial ROS production independently of
NOS.20 The effects of Arg-II on mitochondrial dysfunction are
demonstrated by its ability to decrease mitochondrial mem-
brane potential, another hallmark of mitochondrial dysfunc-
tion.41 That the inactivemutant of Arg-II is as potent aswild-type
Arg-II in inducing H2O2 production and mitochondrial dysfunc-
tion demonstrates enzymatic activity–independent effects of
Arg-II and further supports our conclusion on NOS/NO-inde-
pendent effects of Arg-II in VSMCs.
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Figure 14. Interaction between S6K1, JNK, ERKs, and p66Shc in senescent VSMCs. Immunoblotting analysis of the parameters as indicated. A,
Senescent VSMCs were either untreated () or treated with PD98059 (50 lmol/L) or SP600125 (20 lmol/L) overnight. The line between the
ﬁrst and second lanes indicates cutting of the same blots. B, Senescent VSMCs were transduced with either rAd/U6-LacZshRNA or rAd/
U6-p66ShcshRNA as indicated. Experiments were performed 72 hours posttransduction. Quantiﬁcation of the signals is shown in the
corresponding bar graphs (n=5). *P<0.05, **P<0.01 vs untreated (in A) or LacZshRNA (in B). Arg-II indicates arginase-II; VSMC, vascular smooth
muscle cell; JNK, c-Jun N-terminal kinases; ERK, extracellular signal-regulated kinases; rAd, recombinant adenovirus.
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Key Roles of p66Shc and p53 in Arg-II Enzymatic
Activity–Independent Effects in VSMCs
In an attempt to elucidate the enzymatic activity–independent
effects of Arg-II, we have provided evidence that the mitochon-
drial redox protein p66Shc and p53, which are independently
activated by Arg-II, are the key molecules in mediating
Arg-II-induced mitochondrial dysfunction independently of its
enzymatic activity. This conclusion is supported by the follow-
ing: (1) in young VSMCs, overexpression of either wild-type or
inactive Arg-II increases levels of both p66Shc and phosphor-
ylated p66Shc-S36 as well as p53-S15 with a concomitant
increase in mitochondrial ROS production, a decrease in Dwm,
and an increase in senescence/apoptosis; (2) in senescent
VSMCs, p66Shc and p66Shc-S36 as well as p53-S15 levels are
enhanced in parallel with the upregulation of Arg-II expression
and mitochondrial dysfunction and senescence/apoptosis,
whereas silencing Arg-II in senescent VSMCs decreases
p66Shc-S36 and p66Shc as well as p53-S15 levels with
simultaneous inhibition of mitochondrial dysfunction and
senescence/apoptosis; (3) silencing p66Shc or p53, or over-
expressing p66Shc-S36A, prevents Arg-II-induced mitochon-
drial dysfunction and senescence/apoptosis; (4) targeted
disruption of Arg-II in atherosclerosis-prone ApoE/ mice
(ApoE/Arg-II/ mice) decreases both p66Shc-S36 and
p66Shc as well as p53-S15, and VSMC apoptosis in the plaque.
That the dominant-negative mutant of p66Shc-S36A inhibits
Arg-II-mediated cellular functions in young and senescent
VSMCs demonstrates the functional signiﬁcance of phosphor-
ylation of p66Shc-S36 in these processes. It is interesting to
note that our ﬁndings are also supported by the observation
that Arg-II/ and p66Shc/ mice display similar protective
phenotypes against the development of type 2 diabetes, aging,
and atherosclerosis.11,19–21,42 Our results thus have uncovered
a novel mechanism that Arg-II induces mitochondrial dysfunc-
tion, leading to senescence/apoptosis in VSMCs through
activation of p66Shc and p53. A noteworthy observation is that
the activation of p53 by Arg-II seems independent of the
S6K1-p66Shc pathway, because silencing either S6K1 or
p66Shc does not affect Arg-II-induced p53 activation. However,
its phosphorylation/activation by Arg-II is also required for the
actions of Arg-II in an enzymatic activity–independent manner.
How Arg-II leads to p53 activation remains to be investigated.
Crosstalk Among Arg-II, S6K1, JNK, ERK, and
p66Shc in VSMC Senescence and Apoptosis
Another novel ﬁnding of this study is the role of S6K1 in
Arg-II-induced p66Shc activation in VSMCs. Compelling
evidence has been presented that both S6K1 and p66Shc
are important life-span regulators associated with oxidative
stress and are involved in a number of age-related diseases
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Figure 15. Ablation of Arg-II in atherosclerosis-prone ApoE/mice reduces signaling of S6K1, p66Shc, and p53 in the aortas. ApoE/Arg-II+/+
and ApoE/Arg-II/ mice were fed a high-fat diet for 10 weeks. Aortas from mice of both genotypes were cleaned of perivascular tissues and
subjected to immunoblotting analysis of Arg-II, S6K1, p66Shc-S36 and total p66Shc, p53-S15 and total p53, and S6-S235/236 and total S6.
Tubulin served as a loading control. Quantiﬁcation of the signals is shown in the corresponding lower panels (n=4). *P<0.05, **P<0.001 vs
ApoE/Arg-II+/+. Arg-II indicates arginase-II; ApoE, apolipoprotein E; S6K1, ribosomal protein S6 kinase 1.
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Figure 16. Ablation of Arg-II in atherosclerosis-prone ApoE/ mice reduces levels of Arg-II, S6K1, p66Shc, p53-S15, and p53, as well as PCNA
in VSMCs along with decreased apoptotic VSMCs in atherosclerotic plaque. ApoE/Arg-II+/+ and ApoE/Arg-II/ mice were fed a high-fat diet
for 10 weeks. A, AR-cryosections (7 lm) were subjected to immunoﬂuorescence costaining of Arg-II, S6K1, p66Shc, p53-S15 and p53, and PCNA
with anti-a-smooth muscle actin antibody (a-SMA) for VSMCs. Mouse anti-a-SMA (green) was used for costaining with rabbit antibodies against
Arg-II, p66Shc, p53-S15, and PCNA (red), whereas rabbit anti-a-SMA (red) was used for costaining with mouse anti-p53 and -S6K1 (green). Alexa
Fluor 488–conjugated goat anti-mouse IgG (green) and Alexa Fluor 594–conjugated goat anti-rabbit F(ab)2 (red) were used as secondary
antibodies. All sections were counterstained with DAPI. Representative images of individual staining and merged images are shown (n=4). B,
Representative images showing apoptotic cells detected by TUNEL staining (red) in the plaques in aortic roots of ApoE/Arg-II+/+ and ApoE/
Arg-II/ mice. All sections were stained for VSMCs with anti-a-SMA (green) followed by counterstaining with DAPI for nuclei (blue). The merged
images are also shown (n=4). The white arrows indicate apoptotic VSMCs. Scale bars=0.2 mm. Arg-II indicates arginase-II; ApoE, apolipoprotein
E; S6K1, ribosomal protein S6 kinase 1; VSMC, vascular smooth muscle cell; PCNA, proliferating cell nuclear antigen; DAPI,
406-diamidino-2-phenyl-indole, dihydrochloride; TUNEL, terminal dUTP nick end-labeling.
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including type 2 diabetes and atherosclerosis.43 A linkage
between p66Shc and S6K1 has been previously demon-
strated in adipocytes, in which p66Shc is required for insulin
and nutrient-induced activation of S6K1.42 In our present
study, we have provided evidence that S6K1 mediates
Arg-II-induced activation of p66Shc in VSMCs. Overexpres-
sion of Arg-II enhances S6K1-T389 and S6-S235/236 levels
in young VSMCs, whereas silencing Arg-II in senescent
VSMCs mitigates S6K1-T389 and S6-S235/236 levels.
These results are in line with the ﬁnding that Arg-II positively
regulates S6K1 in endothelial cells.21 Moreover, silencing
S6K1 prevents Arg-II-induced elevation of p66Shc-S36 in
VSMCs. It is noteworthy that silencing p66Shc in VSMCs, in
contrast to the adipocytes,42 does not signiﬁcantly affect
Arg-II-induced S6K1 activation in young VSMCs overexpress-
ing Arg-II. However, it reduces S6K1 activity in senescent
VSMCs. These results demonstrate that p66Shc may operate
both downstream and upstream of S6K1 in VSMCs depend-
ing on the environmental cues. Evidence has been presented
that PKC-b, ERK, and JNK are involved in phosphorylation of
p66Shc-S36.16–18 In the present study, we identiﬁed S6K1
as a protein kinase required for Arg-II-induced phosphoryla-
tion of p66Shc-Ser36. In addition to mediating the phos-
phorylation/activation of p66Shc, S6K1 also upregulates the
protein levels of p66Shc, which is in line with its well-char-
acterized function of promoting protein synthesis. Experi-
ments exploring the interplay between S6K1 and PKC-b,
ERK, and JNK using speciﬁc inhibitors of these signaling
pathways indicate a positive and complex crosstalk between
Arg-II, S6K1, JNK, ERK, and p66Shc in senescent cells.
Although enhanced Arg-II can activate S6K1-JNK and ERK,
leading to phosphorylation/activation of p66Shc that ulti-
mately causes cell senescence, activated p66Shc in senes-
cent cells can in turn, maybe in conjunction with other
altered signaling, activate ERK, JNK, and S6K1, leading to
increased expression of Arg-II. The exact biochemical
mechanisms, for example, whether and how S6K1, ERK,
JNK, and p66Shc interact with each other leading to cellular
senescence and apoptosis, are an interesting topic that
requires further extensive investigation.
A
B
Figure 17. Schematic summary of the major ﬁndings of the study. A, Elevated Arg-II leads to phosphorylation/activation of p66Shc through
S6K1-JNK and ERK in parallel. In addition, Arg-II induces phosphorylation/activation of p53 independently of the S6K1-JNK-p66Shc pathway. Both
S6K1-JNK-p66Shc and p53 are involved in Arg-II-induced H2O2 and mitochondrial dysfunction, which ultimately cause both VSMC senescence and
apoptosis, contributing to plaque vulnerability. Arg-II exerts all these effects independently of its L-arginine ureahydrolase activity, whereas it is
required for VSMC proliferation in an enzymatic activity–dependent manner. B, In senescent VSMCs, Arg-II, S6K1, JNK, ERK, and p66Shc form a
complex positive crosstalk network resulting in acceleration of VSMC aging. Arg-II indicates arginase-II; S6K1, ribosomal protein S6 kinase 1;
VSMC, vascular smooth muscle cell; JNK, c-Jun N-terminal kinases; ERK, extracellular signal-regulated kinases.
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In Vivo Evidence of Arg-II-Induced Activation
of S6K1, p66Shc, and p53 in Atherosclerotic
Plaque-Vulnerable Phenotypes in Mice
Persistent activation of S6K1 signaling, p66Shc, p53, and
excessive ROS production have been shown to cause cellular
senescence and apoptosis through oxidative damage.9–
11,15,16,21,35,44,45 In aging and atherosclerotic plaques, cell
senescence and apoptosis are found to be present in the
vascular wall and are associatedwith plaque vulnerability.3,46,47
In addition to endothelial cells and macrophages, VSMC
senescence and apoptosis are also implicated in unstable
plaques.3–5,7,48,49 In support of this notion, we found that Arg-II,
which activates S6K1, p66Shc, and p53, leads to mitochondrial
ROS production, VSMC senescence, and apoptosis. Further-
more, the role of Arg-II in inducing VSMC apoptosis is reinforced
by the ﬁnding that VSMC apoptosis in aortic plaques is
decreased in ApoE/Arg-II/ mice compared with that in
ApoE/Arg-II+/+ control animals, in parallel with the striking
decrease in S6K1, p66Shc, and p53 in aortic VSMCs.
Noteworthy is that not only phosphorylated levels but also
total levels of S6K1, S6, p66Shc, and p53 are strongly reduced
in ApoE/Arg-II/mice, which is consistent with the results
obtained in senescent VSMCs with silencing Arg-II, although
total p53 is not affected in the cells. These may be explained by
the ﬁnding that S6K1 is implicated in protein translation. The
data on VSMCapoptosis and S6K1-p66Shc and p53 signaling in
ApoE/Arg-II/mice are in agreement with the observations
in our most recently published study showing that, in the
atherosclerosis model, genetic ablation of Arg-II reduces
atherosclerotic plaque formation and confers features of stable
plaques, that is, reduced macrophage accumulation, lower
proinﬂammatory cytokine production, and decreased necrotic
core in the atherosclerotic plaques.20 In addition to enhancing
macrophage proinﬂammatory responses, as reported
recently,20 our present study provides evidence that implicates
the important role of enhanced Arg-II in promoting VSMC
senescence/apoptosis, contributing to unstable plaque. A
deﬁnite answer for the speciﬁc role of Arg-II in VSMCs in plaque
vulnerability shall be further provided by generating VSMC-
speciﬁc Arg-II-knockout mouse.
In conclusion, (Figure 17), in line with a previous report,28
our current study has demonstrated the enzymatic activ-
ity-dependent effect of Arg-II on cell proliferation. Most
importantly, the present study has uncovered a novel mecha-
nism of Arg-II, independently of its L-arginine ureahydrolase
activity, in promoting mitochondrial dysfunction, leading to
VSMC senescence and apoptosis that ultimately contribute to
atherosclerotic plaque instability through the parallel pathways
consisting of Arg-II–S6K1–JNK-p66Shc, Arg-II-ERK-p66Shc,
and Arg-II-p53. Moreover, in senescent VSMCs, Arg-II, S6K1,
JNK, ERK, and p66Shc form a complex positive crosstalk
network resulting in acceleration of VSMC aging. From a clinical
point of view, along with protection against endothelial
dysfunction and macrophage inﬂammation, targeting Arg-II
also exerts beneﬁcial effects on atherosclerosis through
stabilizing atherosclerotic plaque by preventing VSMC senes-
cence and apoptosis.
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